TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self care activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coronary Collateral Flow Index (CFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vertebral kyphosis change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number and types of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality until 12 months of age
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalisations until 12 months of age
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adverse events within 12 months after intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in physical fitness levels as measured by 1RM (repetition maximum) and Cardio-respiratory maximal testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Body composition assessment: DEXA and anthropometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endometriosis related pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the platelet closure time curve from 0-6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macular central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Inspiratory Pressure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gingival inflammation (Modified gingival index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients developing abruption placenta, intrauterine growth retardation or delivered premature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: percentage of fetuses and neonates complicated with intrauterine fetal death or need admission to incubator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Ileal intubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in exhaled nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Oral Intake Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to tobramycin solution initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain levels post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Aleglitazar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preparation for Decision Making Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Informed Subscale of the Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Values Clarity Subscale of the Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects Reporting Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of lead and device parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Bursting pressure of sealed vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body weight (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperactive-Impulsive subscale of the Conners Rating Scale-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician's Global Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: development of contrast induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Markers of the gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Gestational Diabetes Mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from baseline of anxiety subscale in CBCL/ASEBA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes from hyperactivity subscale of ADHDT
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AAD-free freedom from AF/atrial flutter/atrial tachycardia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of plasmatic galectin 3 dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fiberoptic bronchoscopy view
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically significant proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sustained Virologic Response at week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent changes in LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percent changes in hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent changes in sPLA2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antidepressant Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants who develop cancer
Endpoint domain: Mortality/survival
Primary endpoint: Numbers of Treatment Related Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Participation and enjoyment of recess play and socialization
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Eckardt score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of blood product transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Myeloma response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cognitive Impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: evolution of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Significant Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Are Satisfied With IndoProCaf Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma Minocycline Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomics changes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolomics changes in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulmonary deposition of radioaerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Death Rate
Endpoint domain: Mortality/survival
Primary endpoint: Cause Specific Death Rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical/radiographic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescent signal at time of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Muscle Weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance between oesophagus and trachea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ethinylestradiol: Area Under the Curve at Steady State (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levonorgestrel: Area Under the Curve at Steady State (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levonorgestrel: Maximum Measured Concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SARS-CoV-2 in pregnant patients on labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fecal bacteria population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal immunoglobulin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fecal zonulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal short chain fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: eradication of abnormal vaginal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Level of seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in dark-adapted bright flash b-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical effect on scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Distance of single-hop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global haemorrhoidal symptom control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Patency rate of AVG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Efficacy of COVID19 hyper immunoglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of bacterial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Multiorgan failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor outcome at intensive care unit discharge
Endpoint domain: Mortality/survival
Primary endpoint: Reflux symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Placement of the Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in QMG Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of pancreatic fistula within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in nutrition and exercise behavior scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in adolescent sedentary activity time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of adverse events per subject
Endpoint domain: Adverse events/effects
Primary endpoint: Automated volume assessment of acute stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Relief of URI Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUCtau,ss of Ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax,ss of Ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C24,ss of Ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUCtau,ss of Levonogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax,ss of Levonogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progression Free Survival (PFS1)
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (median)
Endpoint domain: Mortality/survival
Primary endpoint: Mean difference of hydrogen sulfide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100 Day Treatment Related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Reduction in Problem Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cure rate of RVVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Star Excursion Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Hot Flash
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in blood intact FGF23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: changes in blood c-term FGF23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrences of Extravasation
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Analysis of breast milk exosomes miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analysis of newborn feces miRNA and intestinal flora analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: UGT1A1 test in newborn blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Blood Pressure at Study Discharge/Early Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Heart Rate at Study Discharge/Early Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Facial Eczema Activity and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Perioral Dermatitis Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Investigator´s Global Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Solicited Injection Site and Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention rate of spontaneous bacterial peritonitis (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subjective alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory psychomotor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG power frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reactive arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Slit Lamp Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in Myosin:Actin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Differences in Force development and Calcium 2+ sensitivity of single muscle fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants with IIEF-EF Score ≥ 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental and Physical Functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Re-Admission to Hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Institutionalisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Score of the Functional Assessment of Cancer Therapy-Breast Quality of Life Instrument (FACT-B)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Episodes of AOM with positive influenza culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Central Nervous System Disease Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in Clinical Activity Score (CAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge score change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Quality of Vision
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Hemoglobin Concentration Maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diurnal IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of Parkinson's Syndrome based on the Movement Disorder Specialist Consensus Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of positive [123I]NAV5001 SPECT brain scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Parkinson's Syndrome based on the on-site neurologist assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of the VITROS hs Troponin I test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Culture conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean defect (MD) measured in decibels (dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucoadhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mouthdrying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemical characterization of propolis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic uptake of 68Ga-NODAGA-exendin-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in normal appearing white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in sexual function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration to maximal sensory block to light touch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of mumps antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes